Clarithromycin
- Generic Name
- Clarithromycin
- Brand Names
- Biaxin, Biaxin Bid, Omeclamox, Prevpac, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C38H69NO13
- CAS Number
- 81103-11-9
- Unique Ingredient Identifier
- H1250JIK0A
- Background
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bacteri...
- Indication
An alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinu...
- Associated Conditions
- Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Acute maxillary sinusitis, Bacterial Infections, Bartonellosis, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Helicobacter Pylori Infection, Infective Endocarditis (IE), Lyme Disease, Mycobacterial Infections, Otitis Media (OM), Pertussis, Streptococcal Pharyngitis, Tonsillitis streptococcal, Uncomplicated skin and subcutaneous tissue bacterial infections
- Associated Therapies
- -
Study on the Efficacy and Safety of Berberine, Minocycline, Esomeprazole, and Colloidal Bismuth Quadruple Therapy in the Initial Treatment of Helicobacter Pylori.
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 548
- Registration Number
- NCT06603688
- Locations
- 🇨🇳
Xijing Hosipital of Digestive Disease, Xian, Shaanxi, China
Drug-Drug Interactions Between TNP-2198 and Midazolam, Clarithromycin
- Conditions
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- TenNor Therapeutics Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06551623
- Locations
- 🇨🇳
The First Hospital of Jinlin University, Changchun, Jilin, China
Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 208
- Registration Number
- NCT06523764
Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication
- Conditions
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 558
- Registration Number
- NCT06514274
- Locations
- 🇨🇳
Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China
A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 38
- Registration Number
- NCT06227832
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit - Los Angeles, Glendale, California, United States
Feasibility Study of the Proposed Test-and-treat Screening Program in Younger Participants With H. Pylori Infection
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- National Institute of Public Health, Slovenia
- Target Recruit Count
- 2000
- Registration Number
- NCT06216639
- Locations
- 🇸🇮
Community Healthcare Center dr. Adolf Drolc Maribor (HCM), Maribor, Slovenia
Vonoprazan for Helicobacter Pylori Eradication in Adolescents
- Conditions
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 242
- Registration Number
- NCT06162949
- Locations
- 🇪🇬
Faculty of Medicine, Alexandria, Egypt
A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 22
- Registration Number
- NCT05965570
- Locations
- 🇺🇸
USA001, Dallas, Texas, United States
A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Miguel O'Ryan Gallardo
- Target Recruit Count
- 500
- Registration Number
- NCT05926804
- Locations
- 🇨🇱
Universidad de Chile, Santiago, Chile
🇨🇱Universidad de Aysén, Coyhaique, Chile
🇨🇱Universidad de la Frontera, Temuco, Chile
Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin
- Conditions
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2023-06-23
- Target Recruit Count
- 22
- Registration Number
- NCT05915871
- Locations
- 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.